Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke (AIS)
Published: December 22, 2015
- While numerous studies and registry data affirm the effectiveness of IV alteplase in AIS, only a minority (3-5%) of patients receive the drug.
- Many of the current exclusions for alteplase are controversial to many stroke experts, with many considering them to be relative or absolute.
- This statement is meant to be adjunctive to the 2013 Acute Ischemic stroke Guidelines.
Supporting Materials
- Commentary: Putting the Patient First: Comments on Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke by Patrick D. Lyden, MD, FAHA
- Top Things to Know: Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke (AIS)
- Slide Set (PDF)